BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Homologous recombination defect is an important biomarker of chemotherapy in certain tumor types, and the presence of pathogenic or likely pathogenic mutations involving BRCA1 or BRCA2 (p-BRCA) mutations is the most well-established marker for the homologous recombination defect. Gastric cancer, one of the most prevalent tumor types in Asia, also harbors p-BRCA mutations. Methods: To investigate the clinical significance of p-BRCA mutations, we analyzed 366 gastric cancer cases through next-generation sequencing. We determined the zygosity of p-BRCA mutations based on the calculated tumor purity through variant allelic fraction patterns and investigated whether the presence of p-BRCA mutations is associated with platinum-based chemotherapy and a certain molecular subtype. Results: Biallelic p-BRCA mutation was associated with better response to platinum-based chemotherapy than heterozygous p-BRCA mutation or wild type BRCA genes. The biallelic p-BRCA mutations was observed only in the chromosomal instability subtype, while all p-BRCA mutations were heterozygous in microsatellite instability subtype. Conclusions: In conclusion, patients with gastric cancer harboring biallelic p-BRCA mutations were associated with a good initial response to platinum-based chemotherapy and those tumors were exclusively chromosomal instability subtype. Further investigation for potential association with homologous recombination defect is warranted.
Abstract
Background: Homologous recombination defect is an important biomarker of chemotherapy in certain tumor types, and the presence of pathogenic or likely pathogenic mutations involving BRCA1 or BRCA2 (p-BRCA) mutations is the most well-established marker for the homologous recombination defect. Gastric cancer, one of the most prevalent tumor types in Asia, also harbors p-BRCA mutations. Methods: To investigate the clinical significance of p-BRCA mutations, we analyzed 366 gastric cancer cases through next-generation sequencing. We determined the zygosity of p-BRCA mutations based on the calculated tumor purity through variant allelic fraction patterns and investigated whether the presence of p-BRCA mutations is associated with platinum-based chemotherapy and a certain molecular subtype. Results: Biallelic p-BRCA mutation was associated with better response to platinum-based chemotherapy than heterozygous p-BRCA mutation or wild type BRCA genes. The biallelic p-BRCA mutations was observed only in the chromosomal instability subtype, while all p-BRCA mutations were heterozygous in microsatellite instability subtype. Conclusions: In conclusion, patients with gastric cancer harboring biallelic p-BRCA mutations were associated with a good initial response to platinum-based chemotherapy and those tumors were exclusively chromosomal instability subtype. Further investigation for potential association with homologous recombination defect is warranted.
참고문헌 (24)
- Smyth EC, "Gastric cancer", Lancet, 396, pp.635~648 (2020)
- Park Sin Hye, "Epidemiology of Gastric Cancer in Korea: Trends in Incidence and Survival Based on Korea Central Cancer Registry Data (1999–2019)", Journal of Gastric Cancer, 22(3), pp.160~168 (2022), 대한위암학회[DOI]
- Johnston FM, "Updates on management of gastric cancer", Curr Oncol Rep, 21, pp.67~ (2019)
- Cunningham D, "Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer", N Engl J Med, 355, pp.11~20 (2006)
- Al-Batran SE, "Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2", 3 trial, 2019, pp.393, 1948~1957
- Ajani JA, "Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 20, pp.167~192 (2022)
- Yan D, "FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer", Zhonghua Zhong Liu Za Zhi, 31, pp.217~219 (2009)
- Patel TH, "Targeted therapies in advanced gastric cancer", Curr Treat Options Oncol, 21, pp.70~ (2020)
- Zhang J, "Chk2 phosphorylation of BRCA1regulates DNA double-strand break repair", Mol Cell Biol, 24, pp.708~718 (2004)
- Mylavarapu S, "Role of BRCA mutations in the modulation of response to platinum therapy", Front Oncol, 8, pp.16~ (2018)
- Kim D, "PARP inhibitors: clinical limitations and recent attempts to overcome them", Int J Mol Sci, 23, pp.8412~ (2022)
- Jonsson P, "Tumour lineage shapes BRCA-mediated phenotypes", Nature, 571, pp.576~579 (2019)
- Jae Myoung Noh, "Associations between BRCA Mutations in High-Risk Breast Cancer Patients and Familial Cancers Other than Breast or Ovary", Journal of Breast Cancer, 15(3), pp.283~287 (2012), 한국유방암학회[DOI]
- Daly MB, "Genetic", familial high-risk assessment:breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology, 2021, pp.19, 77~102
- Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
- Kim JE, "Mutation burden and I index for detection of microsatellite instability in colorectal cancer by targeted next-generation sequencing", J Mol Diagn, 21, pp.241~250 (2019)
- 김문식, "Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors", Cancer Research and Treatment, 55(2), pp.429~441 (2023), 대한암학회[DOI]
- Buchhalter I, "Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis", Int J Cancer, 144, pp.848~858 (2019)
- Talevich E, "CNVkit : genome-wide copy number detection and visualization from targeted DNA sequencing", PLoS Comput Biol, 12, pp.e1004873~ (2016)
- Siegmund SE, "Deriving tumor purity from cancer next generation sequencing data : applications for quantitative ERBB2(HER2)copy number analysis and germline inference of BRCA1 and BRCA2 mutations", Mod Pathol, 35, pp.1458~1467 (2022)
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Sanchez-Vega F, "Oncogenic signaling pathways in The Cancer Genome Atlas", Cell, 173, pp.321~337 (2018)
- Wodarz D, "Passenger mutations can accelerate tumour suppressor gene inactivation in cancer evolution", J R Soc Interface, 15, pp.20170967~ (2018)
- Oza AM, "Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer : a randomised phase 2 trial", Lancet Oncol, 16, pp.87~97 (2015)